Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16323078 | 1.00 | PDE2A (0.44) | PDE2ACYP3A4CYP2B6GPR55OGA | |
| SCHEMBL16324266 | 0.83 | CYP3A4 (0.60) | PDE2ACYP3A4CYP2B6GPR55OGA | |
| SCHEMBL16324269 | 0.83 | CYP3A4 (0.60) | PDE2ACYP3A4CYP2B6GPR55OGA | |
| SCHEMBL21667386 | 0.80 | P2RX3 (0.39) | PDE2AP2RX3SMN1; SMN2 | |
| SCHEMBL16321659 | 0.70 | CYP3A4 (0.48) | CYP3A4CYP2B6P2RX3SMN1; SMN2PGR | |
| SCHEMBL16321660 | 0.70 | CYP3A4 (0.48) | CYP3A4CYP2B6P2RX3SMN1; SMN2PGR | |
| SCHEMBL20901313 | 0.68 | PDE2A (0.48) | PDE2AGPR55OGAACACB | |
| SCHEMBL27046445 | 0.68 | PDE2A (0.48) | PDE2AGPR55OGAACACB | |
| SCHEMBL24469466 | 0.67 | OGA (0.39) | CYP3A4CYP2B6OGA | |
| SCHEMBL879006 | 0.67 | GPR55 (0.45) | PDE2AGPR55OGAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3702352-A1 | PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3010910-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | PDE2A 1079/4885CYP3A4 2600/4885CYP2B6 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.